◆ TICKERBASEOpen interactive view →
◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocksP › POM

Pomdoctor Limited (POM) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Pharmaceutical Retailers · DATA UPDATED 2026-09-08

Pomdoctor Limited (POM) operates in the Pharmaceutical Retailers industry and is headquartered in Guangzhou, China with about 165 employees. Its market capitalization is roughly $8 million. In the fiscal year ended 2025-12-31, POM reported CNY 400M in revenue and (CNY 213M) in net income.

Pomdoctor Limited, through its subsidiaries, offers an online B2C portal to sell pharmaceutical products. The company develops an online medical services platform for chronic diseases in China.

Interactive charts & full statements → Open the POM valuation workbench →

POM Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-31
Total RevenueCNY 400MCNY 343MCNY 305MCNY 245M
Gross ProfitCNY 52MCNY 48MCNY 39MCNY 55M
Operating Income (EBIT)(CNY 116M)(CNY 23M)(CNY 20M)(CNY 3M)
Net Income(CNY 213M)(CNY 143M)(CNY 145M)(CNY 126M)

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

POM Free Cash Flow History

POM Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total AssetsCNY 108MCNY 46MCNY 66MCNY 49M
Total LiabilitiesCNY 589MCNY 2.1BCNY 2.0BCNY 1.9B

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive POM viewer.

Other Companies in Pharmaceutical Retailers

← POLYSPINAll “P” companiesPOMRY →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.